SLC5A2 and fatty liver disease: Hepatic steatosis and liver cirrhosis at baseline were present in 39.7% and 5.6% of the SGLT2 inhibitor group and 37.2% and 6.2% of the non-SGLT2 inhibitor group, respectively.